Products for Research Use Only

PF-03715455

CAT: 0804-HY-18862-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18862-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM) . PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) [1][2].
CAS Number
1056164-52-3
UNSPSC
12352005
Target
P38 MAPK
Type
Reference compound
Related Pathways
MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/pf-03715455.html
Purity
98.44
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
CC(C)(C1=NN(C2=CC=C(O)C(Cl)=C2)C(NC(NCC3=CC=CC=C3SC4=CN5C(C6=CC=CC=C6SCCO)=NN=C5C=C4)=O)=C1)C
Molecular Formula
C35H34ClN7O3S2
Molecular Weight
700.27
References & Citations
[1]Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24 (3) :383-92.|[2]Millan DS, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2011 Nov 24;54 (22) :7797-814.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
P38α; p38β